Vir Biotechnology Inc. VIR, +4.50% said Tuesday that it began dosing participants in a Phase 2 clinical trial evaluating its experimental monoclonal antibody to prevent illness from influenza A. The investigational therapy is an intramuscular dose that has been designed to prevent seasonal flu and influenza A, which has previously caused flu pandemics, including the H1N1 pandemic in 2009. The randomized, double-blind, placebo-controlled study will enroll 3,0000 healthy adults, and the first batch of data from the trial is expected to be available in mid-2023. Vir’s stock has declined 48.4% this year, while the S&P 500 SPX, +2.65% is down 24.9%.
